Fibrogen, Inc.

Hoechst Aktiengesellschaft

Thomas Jefferson University

Academy of Finland

Kari I Kivirikko

Thomas B Neff

Taina Pihlajaniemi

Darwin J Prockop

Dietrich Brocks

David R Olsen

Andrzej Fertala

Leena M Ala-Kokko

Aleksander Sieron

James W Polarek

Amy Geddis

Robert C Chang

Georg Tschank

Stephan Henke

Volkmar Gunzler

Hartmut Hanauske-Abel

Jurgen Mohr

Volkmar Gunzlen-Pukall

Raili M Myllyla

Minna Kristiina Nokelainen

Ritva Kaarina Nissi

Pia Pauliina Annunen

Tarja Inkeri Helaakoski

Karl A Piez

George Martin

Kari Majamaa

The present invention relates to recombinant gelatins and compositions thereof, and methods of producing and using the same.

Recombinant gelatins

The present invention relates to novel isoforms of the .alpha. subunit of prolyl-4-hydroxylase, polynucleotide sequences encoding these novel proteins, and methods for making such proteins.

.alpha.2 subunit of prolyl-4-hydroxylase, nucleic acid sequences

The invention provides novel methods and compositions for the treatment of immune system-mediated arthritis, including rheumatoid arthritis. The subject compositions comprise one or more different types of collagen or collagen derivatives and a mucosa binding structure. Specific combinations of collagen and/or collagen derivatives may be used to treat specific types of arthritis. The collagen(s) and/or collagen(s) derivatives used in the subject compositions may be either obtained from natural sources or produced by recombinant genetic engineering techniques by chemical modification. Another aspect of the invention is to provide methods for treating various types of arthritis by administering an effective amount of the subject collagen-containing compositions. The methods of the invention involve the oral administration of a collagen or collagens found in a specific tissue, e.g., cartilage, so as to induce the suppression (immunological tolerance) of inflammation against the tissue from which the collagen is found to occur in nature. The methods of the invention include the administration of the subject collagen(s) and/or collagen derivative(s) containing compositions into the intestines so as to induce immune tolerance, e.g., oral administration.

Collagen-based methods and formulations for the treatment of arthritis

The invention is transfected cells, substantially all of which contain at least one human collagen gene and express fibrillar collagen molecules derived using methods for synthesizing collagen and collagen fibrils in said cell lines, and methods for treatment of disorders in humans using said collagen derived from said stable cell lines.

Synthesis of human procollagens and collagens in recombinant DNA systems

The invention is stably transfected cells, substantially all of which contain at least one human collagen gene and express fibrillar collagen molecules derived using methods for synthesizing collagen and collagen fibrils in said cell lines, and methods for treatment of disorders in humans using said collagen derived from said stable cell lines.

The invention relates to compounds of the formula I ##STR1## in which A denotes an optionally substituted radical from the series comprising alkyl, acyl, cycloalkyl, aryl and heteroaryl; Cyc represents an optionally substituted heterocyclic carbonyl compound; D represents NH, NCH.sub.3, O or CH.sub.2 ; E represents CHOH, CO, SO or optionally N-substituted C.dbd.NH; F represents O, NH, NCH.sub.3 or a bond; R.sup.4 denotes an optionally substituted radical from the series comprising alkyl, cycloalkyl, aryl and heteroaryl; and R.sup.8 denotes hydrogen or optionally substituted alkyl, to a process for the preparation thereof, and to the use thereof as inhibitors of prolyl hydroxylase.

Oligopetides with cyclic proline-analogous amino acids

Esters of pyridine-2,4- and -2,5-dicarboxylic acid act as inhibitors of proline hydroxylase and lysine hydroxylase and are suitable as fibrosuppressants and immunosuppressants, in particular for the treatment of disturbances of the metabolism of collagen and collagen-like substances and of the biosynthesis of Cl.sub.q.

Esters of pyridine-2,4- and 2,5-dicarboxylic acid as medicaments for the

Growing community of inventors

Oulu, Finland

Kari I Kivirikko